Combination chemoimmunotherapy with pentostatin, cyclophosphamide, and rituximab shows significant clinical activity with low accompanying toxicity in previously untreated B chronic lymphocytic leukemia

Building on the prior work of use of pentostatin in chronic lymphocytic leukemia (CLL), we initiated a trial of combined pentostatin (2 mg/m(2)), cyclophosphamide (600 mg/m(2)), and rituximab (375 mg/m(2)) for 65 symptomatic, previously untreated patients. Of 64 evaluable patients, 34 (53%) were hig...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Main Authors: Kay, Neil E., Geyer, Susan M., Call, Timothy G., Shanafelt, Tait D., Zent, Clive S., Jelinek, Diane F., Tschumper, Renee, Bone, Nancy D., Dewald, Gordon W., Lin, Thomas S., Heerema, Nyla A., Smith, Lisa, Grever, Michael R., Byrd, John C.
Formato: Artigo
Idioma:Inglês
Publicado em: American Society of Hematology 2007
Assuntos:
Plenary Paper
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC1785105/
https://ncbi.nlm.nih.gov/pubmed/17008537
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1182/blood-2006-07-033274
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados